Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 9/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18294652 | 0.85 | ALDH1A1 (0.42) | MEN1KMT2ANPC1POLBHPGD | |
| SCHEMBL18294655 | 0.81 | MEN1 (0.43) | MEN1KMT2ANPC1POLBHPGD | |
| SCHEMBL18296578 | 0.75 | CALM1 (0.43) | MEN1KMT2ANPC1POLBHPGD | |
| SCHEMBL10200347 | 0.71 | APEX1 (0.39) | MEN1KMT2ANPC1POLBHPGD | |
| SCHEMBL2796397 | 0.71 | MAPT (0.47) | MEN1KMT2ANPC1POLBHPGD | |
| SCHEMBL10200458 | 0.70 | — | — | |
| SCHEMBL10200459 | 0.69 | HPGD (0.35) | MEN1KMT2ANPC1POLBHPGD | |
| SCHEMBL18294654 | 0.68 | KDM4E (0.40) | MEN1KMT2ANPC1HPGDKDM4E | |
| SCHEMBL339858 | 0.67 | KDM4E (0.39) | MEN1KMT2ANPC1HPGDKDM4E | |
| SCHEMBL2798780 | 0.66 | KMT2A (0.45) | MEN1KMT2ANPC1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160354361-A1 | NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY | TAIRX INC. (TW) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354361-A1 | NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY | TEK, FLT1, VHL | MEN1 754/4885KMT2A 776/4885NPC1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.